Gradientech closes USD 2.1 million in oversubscribed rights issue
Gradientech has closed an oversubscribed rights issue among its existing shareholders for a total of USD 2.1 million. “We are very happy for the continued trust from our current investors in these uncertain times. Sepsis has been identified as a major complication in Covid-19 patients and this investment allows us to continue our significant work towards the market introduction of our diagnostic system for very rapid antibiotic resistance testing, essential for sepsis patient survival”, says Sara Thorslund, CEO Gradientech.
Next-generation antimicrobial susceptibility testingTake a look at our E-book